Key Takeaways Bayer's phase III OCEANIC-STROKE trial showed asundexian cut recurrent ischemic stroke risk by 26%.BAYRY said the drug met safety goals, with no increase in major bleeding versus placebo.Bayer plans to submit the data for approval, strengthening its cardiovascular pipeline and growth outlook.Bayer (BAYRY) presented positive results from the late-stage OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, factor XIa inhibitor asundexian (50mg) compared to placebo, bo ...